Time and date for telephone conference related to the publishing of the interim report for Q1 2012

5/25/2012 9:12 AM EST

Topotarget
Investor News

Time and date for telephone conference related to the publishing of the interim
report for Q1 2012

To NASDAQ OMX Copenhagen A/S
Investor News No. 03-12 / Copenhagen, May 25, 2012



Copenhagen, Denmark – May 25, 2012 – Today Topotarget A/S (NASDAQ OMX: TOPO)
announced that a telephone conference will be held on May 30, 2012 at 11:00 am
CET. The executive management will present the interim report for Q1 2012 and
answer questions. The teleconference will be conducted in English. A
presentation will be available on Topotarget’s website, www.topotarget.com,
before the start of the conference call. 



To participate in the conference call please dial:



  -- From Denmark: +45 70 26 50 40 or +45 70 27 90 09
  -- Outside Denmark: +44 208 817 9301 (international)



A replay of the conference call will be available approximately three hours
after the conference call and until July 29, 2012 at: 004570252601 or
0035314364267, pass code: 7294 826#. A replay of the conference call will also
be available on Topotarget's homepage www.topotarget.com. 





Topotarget A/S



For further information, please contact:

Anders Vadsholt, CFO – direct: +45 39 17 83 45; Cell: +45 28 98 90 55



Background information

About Topotarget

Topotarget (NASDAQ-OMX: TOPO) is an international biopharmaceutical company
headquartered in Copenhagen, Denmark, dedicated to clinical development and
registration of oncology products. Topotarget focuses, in collaboration with
Spectrum Pharmaceuticals, Inc., on the development in pivotal studies of its
lead drug candidate, belinostat, which has shown positive results as a
monotherapy treating hematological malignancies and positive results in solid
tumors. Belinostat may be used in combination with full doses of chemotherapy,
and is in a pivotal trial within PTCL (peripheral T-cell lymphoma). For more
information, please refer to www.topotarget.com. 



Topotarget A/S Safe Harbor Statement

This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. Topotarget A/S cautions investors
that there can be no assurance that actual results or business conditions will
not differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
Topotarget A/S will not proceed as planned for technical, scientific or
commercial reasons or due to patient enrolment issues or based on new
information from non-clinical or clinical studies or from other sources; the
success of competing products and technologies; technological uncertainty and
product development risks;  uncertainty of additional funding; Topotarget A/S'
history of incurring losses and the uncertainty of achieving profitability;
Topotarget A/S' stage of development as a biopharmaceutical company; government
regulation; patent infringement claims against Topotarget A/S' products,
processes and technologies; the ability to protect Topotarget A/S' patents and
proprietary rights; uncertainties relating to commercialization rights; and
product liability exposure. We disclaim any intention or obligation to update
or revise any forward-looking statements, whether as a result of new
information, future events, or otherwise, unless required by law.